SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending due to the accelerated path of its oral obesity drug, VK2735, directly into Phase 3 following positive FDA feedback, fueling community discussions about a significant short squeeze and potential lucrative partnership or acquisition in the booming GLP-1 market.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforce is experiencing a significant sell-off, caught in a broader market fear that AI will disrupt and displace traditional enterprise software, leading to a "Death By AI" narrative across the sector. Many investors view the sharp decline as an irrational overreaction, highlighting the company's strong fundamentals and ongoing AI integration as a major buying opportunity.

QuantumScape Corp. engages in developing next-generation solid-state lithium-metal batteries. The company’s next-generation batteries are designed to enable greater energy density, faster charging, and enhanced safety to support the transition away from legacy energy sources toward a lower-carbon future. The company was founded by Jagdeep Singh, Tim Holme, and Fritz B. Prinz in May 2010 and is headquartered in San Jose, CA.

QuantumScape Corp - Ordinary Shares - Class A

QuantumScape Corp

QuantumScape is trending as the community hotly debates the significance of its newly operational "Eagle Line" pilot production facility and recent videos showcasing it. Bulls anticipate massive long-term upside from its solid-state battery technology, while bears criticize the lack of immediate revenue and extended commercialization timelines.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

Churchill Capital Corp X (CCCX) is trending with an imminent merger into Infleqtion (INFQ) on NYSE, fueling investor excitement around its leading quantum technology, significant NASA and DOE contracts, and strong institutional confidence. The community is actively debating its undervalued status compared to peers, with high expectations for its debut as a key player in quantum computing and sensing.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Energy and Transportation, Financial Products, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Energy and Transportation segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The Financial Products segment provides financing alternatives to customers and dealers for Caterpillar products and services, as well as financing for power generation facilities. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925 and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending after reporting strong earnings, with its power generation segment surging due to robust demand for turbines and gensets from AI data centers, leading to record highs and analyst upgrades. The community is actively discussing whether its current valuation is justified, as the industrial giant is now viewed by many as a key beneficiary of the ongoing AI infrastructure buildout.

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NovoCure Ltd

NovoCure is trending after its Optune Pax received FDA approval for locally advanced pancreatic cancer, hailed as the first new treatment in three decades, driving community debate on its modest survival benefit, considerable commercial potential, and the stock's near-term trajectory amidst skepticism.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly Inc is trending after reporting a significant earnings beat and robust guidance, marking its first profitable fiscal year with record revenue and gross margins. The community is actively discussing this as a potential turnaround story, driven by new leadership and increasing AI tailwinds in the edge computing sector, though some remain cautious given its past.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is trending following its stellar earnings report, initially marred by corrected erroneous news of a miss and a major short-seller retraction of prior allegations, prompting community discussion about market manipulation and a potential rebound. Investors are focused on the company's impressive growth, strong cash flow, and high profit margins, which many believe were undervalued by the initial reaction to misinformation.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco is a top trending stock following strong earnings and an optimistic outlook driven by accelerating AI infrastructure orders, though initial after-hours trading reflected market concerns over gross margins. The community is debating whether the company's valuation is justified by its renewed growth and strategic positioning in the AI era, especially as its share price approaches a multi-decade high.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is seeing heavy selling pressure sparked by T-Mobile's new AI translation service, intensifying community debate over whether AI will render language learning apps obsolete. Despite the company's strong fundamentals and user growth, investors remain sharply divided between those calling the market reaction irrational and a major buying opportunity, and those forecasting further declines.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire TEL AVIV, Israel, Jan...

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting

Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting PR...

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH

Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH Galmed Announces Grant of New Use Patents for the combination...

Galmed Issues CEO Letter to Shareholders

Galmed Issues CEO Letter to Shareholders Galmed Issues CEO Letter to Shareholders PR Newswire TEL AVIV, Israel, Dec. 1, 2025 TEL AVIV, Israel, Dec. 1, 2025 /PRNewswire/ -- Galmed Pharmaceuticals Ltd...

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PR...

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine

Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine PR Newswire RAMAT-GAN...

<ul class="summary-bullets"><li>Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.</li><li>The company plans to begin Phase 1b trials in early 2026 as key Stivarga patents near expiration.</li><li>Stocktwits users focused on possible dilution, SEC filings, and the timing of upcoming earnings.</li></ul>Galmed Pharmaceuticals shares&nbsp;rose on Monday, following four sessions of losses, after the company reported top-line results showing that a three-drug combination of Aramchol, Stivarga and Metformin significantly improved tumor-cell killing in gastrointestinal cancers.The stock closed up 1% at $1.05 before slipping 4.6% in after-hours trading.<h2 class="st-heading-2">Top-Line Results Highlight Triple-Drug Effect</h2>Galmed said the regimen of Aramchol, Stivarga and Metformin demonstrated a significant synergistic effect, improving tumor-cell killing both in vivo and in vitro. The company said the combination&nbsp;could be developed as a fixed-dose therapy that could strengthen the effect of Stivarga, Bayer’s top-selling cancer drug.According to the company, the combination may serve as a life-cycle IP strategy for Stivarga as key patents expire in Europe in August 2028 and in the U.S. in July 2032. Two new U.S. patent applications have been submitted.Galmed said the Aramchol-Stivarga combination is expected to enter Phase 1b clinical trials in early 2026 for metastatic colorectal cancer, hepatocellular carcinoma and cholangiocarcinoma, with a planned expansion cohort including Metformin.<h2 class="st-heading-2">Study Builds On Prior Findings</h2>An earlier May study reported that Aramchol enhanced the efficacy of regorafenib in gastrointestinal cancer models. In that study, Aramchol&nbsp;enhanced the breakdown of cellular material triggered by regorafenib and affected several cell-signaling pathways linked to tumor growth. The combination also reduced tumor growth in liver cancer models without harming normal tissue.The newly announced results include additional data on&nbsp;the use of Aramchol in combination with regorafenib and Metformin. The study reported that Aramchol showed anti-tumor activity on its own and when&nbsp;combined with the other two drugs, and that the three-drug combination produced a reinforcing effect, supporting further development as a combined treatment.<h2 class="st-heading-2">Clinical Path Ahead</h2>Allen Baharaff said a fixed-dose combination with Aramchol “could potentially become a life-cycle IP strategy for regorafenib to help delay the generic competition.”Baharaff said the company is preparing to initiate its Phase 1b study at VCU Massey Comprehensive Cancer Center in early 2026. He added that positive findings could support accelerated development of Aramchol across three gastrointestinal cancer indications and expand the company’s pipeline.<h2 class="st-heading-2">Stocktwits Users Flag Possible Dilution</h2>On Stocktwits, retail sentiment for Galmed was ‘extremely bullish’ amid a 12,950% surge in 24-hour message volume.<figure class="image"><img style="aspect-ratio:968/143;" src="https://news.stocktwits-cdn.com/glmd_ss_jpg_a183d03fe6.webp" alt="glmd ss.jpg" width="968" height="143"><figcaption>GLMD sentiment and message volume as of November 17 | Source: Stocktwits</figcaption></figure>One user said, “Now let's wait for SEC filing. Crossed my fingers. I will tell you, if no dilution SEC is filed today after market close or before market opens, then get ready for another run and this would be epic run”<stembedurl>https://stocktwits.com/madan_shatri/message/636516948</stembedurl>Another user commented that they anticipated earnings “any day” and suggested the stock might attempt “a runup” before a potential offering.<stembedurl>https://stocktwits.com/Jonsie/message/636511939</stembedurl>Galmed’s stock has declined 67% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, the Galmed Pharmaceuticals logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Galmed Pharmaceuticals Stock Snaps 4-Day Losing Streak On Triple-Drug Cancer Breakthrough — Retail Sees Dilution Risks

Galmed reported new data showing that its Aramchol–Stivarga–Metformin combination improved tumor cell killing in GI cancer models.

Equity

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro

Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro Galmed...

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update PR...

Galmed Pharmaceuticals (GLMD) shares rose sharply on Tuesday after the company reported positive preclinical data showing that its experimental drug Aramchol enhances the effectiveness of Regorafenib in liver and colon cancer models.Following the announcement, Galmed's stock rose by 10.6%, closing at $1.46 per share.&nbsp;According to the company, Aramchol improved the anti-tumor activity of Regorafenib — a multi-kinase inhibitor approved for liver and colorectal cancers — in both in-vitro and in-vivo settings.&nbsp;The combination also activated ATM and AMPK pathways while inhibiting mTORC1 and mTORC2, mechanisms known to play roles in cancer cell survival.Aramchol was also shown to work in combination with other kinase inhibitors like Sorafenib and Lenvatinib, though Regorafenib exhibited the strongest synergistic effects.&nbsp;The dual treatment suppressed tumor growth in hepatoma models without causing toxicity to normal tissues, the company said.Retail sentiment spiked following the update.&nbsp;On Stocktwits, message volume surged 4,480% over 24 hours, with sentiment marked as ‘extremely bullish.’Some retail investors suggested the stock could double from a previous $1.31 entry level.&nbsp;<stembedurl>https://stocktwits.com/debbiekatz/message/613719065</stembedurl>Others speculated the price could climb to the $2.50–$3.00 range, reflecting confidence ahead of the next trading session.<stembedurl>https://stocktwits.com/ZCOCSTOCK/message/613738896</stembedurl>Galmed said it expects to initiate a Phase 1b trial of Aramchol in combination with Regorafenib by the fourth quarter of 2025.The oncology update comes on the heels of another strategic development.&nbsp;Last week, Galmed signed a binding term sheet with Entomus s.r.o. for the licensing of a proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation.&nbsp;The technology enables sublingual absorption of peptides such as GLP-1, a key target in metabolic disorders.&nbsp;A definitive agreement outlining milestones and royalty terms is expected within 90 days.Shares of Galmed have fallen 56% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RBC said Medicaid spending was politically harder to unwind than the Journal suggested, adding that many small and rural hospitals depend on these payments to stay afloat. | Image source: Getty Images

Galmed Pharma Shares Jump 10% On Cancer Drug Data: Retail Traders Turn ‘Extremely Bullish’

The company reported that Aramchol, its experimental liver drug, enhanced Regorafenib’s anti-tumor effects without causing toxicity in preclinical models.

Galmed Pharmaceuticals Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Galmed Pharmaceuticals Ltd

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COIN earnings on Thursday?

GLMD
Galmed Pharmaceuticals Ltd

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest GLMD News

GLMDGalmed Pharmaceuticals Ltd